Elite Pharmaceuticals, Inc.
ELTP
$0.37
$0.00-0.62%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 40.75M | 31.59M | 36.32M | 40.21M | 32.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.75M | 31.59M | 36.32M | 40.21M | 32.00M |
| Cost of Revenue | 19.98M | 18.64M | 22.25M | 12.99M | 14.70M |
| Gross Profit | 20.77M | 12.95M | 14.07M | 27.23M | 17.30M |
| SG&A Expenses | 7.73M | 2.51M | 4.08M | 3.46M | 2.09M |
| Depreciation & Amortization | 370.00K | 388.10K | 394.90K | 394.90K | 409.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.71M | 22.58M | 28.11M | 18.51M | 19.24M |
| Operating Income | 11.03M | 9.01M | 8.21M | 21.70M | 12.76M |
| Income Before Tax | 20.85M | 20.83M | 15.69M | -564.20K | 19.27M |
| Income Tax Expenses | 2.39M | 2.24M | 1.99M | 5.32M | 2.27M |
| Earnings from Continuing Operations | 18.46M | 18.59M | 13.70M | -5.88M | 17.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.46M | 18.59M | 13.70M | -5.88M | 17.00M |
| EBIT | 11.03M | 9.01M | 8.21M | 21.70M | 12.76M |
| EBITDA | 11.40M | 9.40M | 8.61M | 22.09M | 13.17M |
| EPS Basic | 0.02 | 0.02 | 0.01 | -0.01 | 0.02 |
| Normalized Basic EPS | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 |
| EPS Diluted | 0.01 | 0.01 | 0.01 | -0.01 | 0.02 |
| Normalized Diluted EPS | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 |
| Average Basic Shares Outstanding | 1.08B | 1.07B | 1.07B | 1.07B | 1.07B |
| Average Diluted Shares Outstanding | 1.19B | 1.14B | 1.14B | 1.07B | 1.07B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |